Boehringer In­gel­heim to in­cu­bate biotechs with Hong Kong R&D leader

Fol­low­ing the suit of As­traZeneca last Feb­ru­ary, Boehringer In­gel­heim will team up with a lead­ing R&D hub in Hong Kong to seed biotechs.

Where­as As­traZeneca fo­cused on can­cer drugs and di­ag­nos­tics, the Ger­man gi­ant will work with Hong Kong Sci­ence and Tech­nol­o­gy Parks on in­cu­bat­ing in­fec­tious dis­ease and im­munol­o­gy drug de­vel­op­ers.

HK­STP and Boehringer, through its ven­ture arm, will sup­port the up­starts with up to $6 mil­lion HK (about $600,000 USD) each to bankroll ear­ly-stage op­er­a­tions and clin­i­cal tri­als, said Grace Lau, head of HK­STP’s in­sti­tute for trans­la­tion­al re­search, in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER